Clinical Trial Search

Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Parental Anxiety — 4.2; 3.9 points on a scale

Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations

Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change

Primary: Percentage of Clinical Cure (Success) at Test of Cure Visit(Clinical Per Protocol Population) — 93.0; 94.2; 7.0; 5.8 percent

Primary: 24 Hour Sputum Volume — 41.8; 23.6; 29.9; 26.2 gram — p=<0.01

Primary: Difference in Mucociliary Clearance (MCC) Between Visit 1A and Visit 2A — -1.50; -0.70 percentage difference of MCC

Primary: Mean Rate of Wheezing Attacks — 3.57; 5.72 wheezing attacks/per patient — p=0.05

Primary: Change From Baseline in Total Bacterial Load in the Sputum at End of Treatment (Day 29). — -2.94; -0.32 log10 of CFU per gram sputum — p=< 0.001

Primary: Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic — 0.019; -0.005 Litre — p=0.216

Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305

Primary: Number (%) of Patients With Drug-related Adverse Events (AEs) — 7; 7; 10; 14 percentage of participants

Primary: Length of Stay in the Study-LOS--Intention to Treat Analysis — 2.1; 2.1 Days — p=0.73

Primary: Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period — -1.75; -0.73 Score…

Primary: Length of Stay in the Hospital — 38.7; 39.5 hours — p=<0.05

Primary: Number of Coughs Following Capsaicin Inhalation Challenge at Baseline and Following 30 Days of Treatment With Spiriva (Baseline and 30 Days) — 2.5 coughs per dose of…

Primary: Nontuberculous Mycobacterial (NTM) Disease — 188; 32 Events — p=0.19

Primary: Duration of Cough — 13; 11 days

Primary: Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) at 8 Weeks — 60; 71; 84; 69 cmH2O — p=0.005

Primary: All Cause Mortality — 0; 1 participants

Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year

Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115

Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85

Primary: Number of Patients Who Were Cured — 91; 117 Participants — p=<0.05

Primary: St. George's Respiratory Questionnaire (SGRQ) Scores at Baseline and End of Treatment — 69.6; 67.4; 61.0; 64.5 units on a scale

Primary: Score Respiratory Distress — 8; 8; 6; 8 units on a scale

Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml

Primary: Annualized Rate of Pulmonary Exacerbations (PEs) — 1.015; 1.036; 1.286 exacerbation per participant-year — p==0.0019

Primary: The Primary Outcome is the Change in Bronchodilation and Bronchoprotection After Broccoli Sprout Extract — 10.3; 26.7 index